<p>Ausdal Financial Partners Inc. 在第三季度购买了 Exact Sciences Corporation (NASDAQ:EXAS - 免费报告) 的新股份，根据其最近向证券交易委员会的披露。这家机构投资者购买了 90,988 股这家医疗研究公司的股票，价值约为 4,978,000 美元。</p>
<p>获取 <strong>Exact Sciences</strong> 的提醒：</p>
<ul>
<li>Myriad Genetics 的遗传癌症检测使股票飙升</li>
</ul>
<p>其他几家机构投资者也增加或减少了在 EXAS 的持股。Westside Investment Management Inc. 在第三季度将其在 Exact Sciences 的持股提高了 100.0%。Westside Investment Management Inc. 目前拥有 542 股这家医疗研究公司的股票，价值 31,000 美元，此前在该期间额外购买了 271 股。Country Trust Bank 在第二季度购买了 Exact Sciences 的新股份，价值 32,000 美元。Quent Capital LLC 在第三季度购买了 Exact Sciences 的新股份，价值 48,000 美元。OFI Invest Asset Management 在第三季度将其在 Exact Sciences 的持股增加了 241.2%。OFI Invest Asset Management 目前拥有 1,085 股这家医疗研究公司的股票，价值 59,000 美元，此前在上个季度额外购买了 767 股。最后，Parallel Advisors LLC 在第三季度将其在 Exact Sciences 的持股提高了 47.6%。Parallel Advisors LLC 目前拥有 1,179 股这家医疗研究公司的股票，价值 65,000 美元，此前在该期间额外购买了 380 股。当前 88.82% 的股票由机构投资者持有。</p>
<h2>分析师设定新目标价</h2>
<p>几家研究公司最近对 EXAS 进行了评估。William Blair 在 11 月 20 日的研究报告中将 Exact Sciences 的评级从 “跑赢大盘” 下调至 “市场表现”。Weiss Ratings 在 1 月 22 日的研究报告中重申了对 Exact Sciences 股票的 “卖出 (d-)” 评级。Evercore 在 1 月 5 日的研究报告中设定了 Exact Sciences 的目标价为 105.00 美元，并给予该公司 “持平” 评级。Wells Fargo &amp; Company 在 11 月 20 日的研究报告中重申了 “等权重” 评级，并将 Exact Sciences 的目标价设定为 105.00 美元（上调自 85.00 美元）。最后，Barclays 在 11 月 20 日的报告中重新发布了 “等权重” 评级，并将 Exact Sciences 的目标价设定为 105.00 美元（上调自 77.00 美元）。21 位分析师对该股票给予了持有评级，1 位分析师给予了卖出评级。根据 MarketBeat.com 的数据，该公司目前的平均评级为 “减持”，平均目标价为 92.13 美元。</p>
<ul>
<li>国会议员购买的 3 只热门股票：跟随资金流动</li>
</ul>
<p><strong>查看我们最新的 Exact Sciences 股票报告</strong></p>
<h2>Exact Sciences 股票上涨 0.3%</h2>
<p>EXAS 的股票在周五开盘价为 103.57 美元。该公司的市值为 197.7 亿美元，市盈率为 -94.15，市盈增长比率为 2.36，贝塔值为 1.41。该公司的债务与股本比率为 0.97，流动比率为 2.43，速动比率为 2.17。Exact Sciences Corporation 的一年低点为 38.81 美元，一年高点为 103.75 美元。该公司的 50 日简单移动平均为 102.83 美元，200 日简单移动平均为 83.86 美元。</p>
<ul>
<li>现在是购买这 3 家提高收入指引的医疗公司吗？</li>
</ul>
<p>Exact Sciences (NASDAQ:EXAS - 获取免费报告) 最近在 2 月 13 日发布了其财报。这家医疗研究公司报告了本季度每股收益为（$0.21），低于共识预期的 $0.08，差距为（$0.29）。Exact Sciences 的股本回报率为 0.53%，净利润率为 -6.40%。在去年同期，该公司每股收益为（$0.06）。该公司的收入同比增长 23.1%。分析师平均预计 Exact Sciences Corporation 本财年的每股收益将为 -0.58。</p>
<h2>Exact Sciences 公司简介</h2>
<p>(免费报告)</p>
<p>Exact Sciences Corporation 是一家分子诊断公司，总部位于威斯康星州麦迪逊，致力于癌症的早期检测和预防。该公司的旗舰产品 Cologuard® 是一种非侵入性的基于粪便的 DNA 筛查测试，用于结直肠癌，由 Mayo Clinic 合作开发。通过结合 DNA 突变分析和血红蛋白检测，Cologuard 旨在提高筛查依从性，并在平均风险成年人中识别癌症和癌前病变。</p>
<p>自 1995 年成立以来，Exact Sciences 通过战略收购和内部研发扩展了其产品组合。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们更看好的股票超过 Exact Sciences</li>
<li>华尔街害怕的黄金图表……</li>
<li>埃隆·马斯克已经让我成为 “富有的人”</li>
<li>白银支付 20% 股息。此外 68% 的股票收益</li>
<li>解锁：埃隆·马斯克的下一个大 IPO</li>
<li>马丁·韦斯的个人警告（请阅读）</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RVhBUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RVhBUw"/></p>
<p><em>此即时新闻提醒由叙述科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Exact Sciences 吗？</h2>
<p>在你考虑 Exact Sciences 之前，你会想听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Exact Sciences 并不在名单上。</p>
<p>虽然 Exact Sciences 目前在分析师中获得了减持评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

标普生物技术 ETF - SPDR

美国医疗保健供应商 ETF - iShares

医疗业 ETF - SPDR

<p>Ausdal Financial Partners Inc. 已经收购了 Exact Sciences Corporation 的新股份，购买了 90,988 股，价值约 498 万美元。其他机构投资者也调整了他们在 EXAS 的持仓。分析师对该股票的看法不一，William Blair 将其评级下调至 “市场表现”，而 Wells Fargo 则将其目标价上调至 105 美元。Exact Sciences 在最新的财报中报告每股收益亏损 0.21 美元，未能达到预期，但收入同比增长 23.1%。该股票目前交易价格为 103.57 美元，市值为 197.7 亿美元</p>

<p>Ausdal Financial Partners Inc. bought a new stake in shares of Exact Sciences Corporation (NASDAQ:EXAS - Free Report) in the third quarter, according to its most recent disclosure with the Securities &amp; Exchange Commission. The institutional investor bought 90,988 shares of the medical research company's stock, valued at approximately $4,978,000.</p>
<div class="lb-trans"><p>Ausdal Financial Partners Inc. 在第三季度购买了 Exact Sciences Corporation (NASDAQ:EXAS - 免费报告) 的新股份，根据其最近向证券交易委员会的披露。这家机构投资者购买了 90,988 股这家医疗研究公司的股票，价值约为 4,978,000 美元。</p>
</div><p>Get <strong>Exact Sciences</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Exact Sciences</strong> 的提醒：</p>
</div><ul>
<li>Myriad Genetics Sees Stock Surge with Hereditary Cancer Tests</li>
</ul>
<div class="lb-trans"><ul>
<li>Myriad Genetics 的遗传癌症检测使股票飙升</li>
</ul>
</div><p>Several other institutional investors have also added to or reduced their stakes in EXAS. Westside Investment Management Inc. raised its position in Exact Sciences by 100.0% in the third quarter. Westside Investment Management Inc. now owns 542 shares of the medical research company's stock worth $31,000 after acquiring an additional 271 shares during the period. Country Trust Bank bought a new stake in shares of Exact Sciences during the 2nd quarter valued at $32,000. Quent Capital LLC purchased a new stake in shares of Exact Sciences in the 3rd quarter worth $48,000. OFI Invest Asset Management increased its stake in shares of Exact Sciences by 241.2% in the 3rd quarter. OFI Invest Asset Management now owns 1,085 shares of the medical research company's stock worth $59,000 after purchasing an additional 767 shares in the last quarter. Finally, Parallel Advisors LLC raised its holdings in Exact Sciences by 47.6% in the 3rd quarter. Parallel Advisors LLC now owns 1,179 shares of the medical research company's stock worth $65,000 after purchasing an additional 380 shares during the period. 88.82% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>其他几家机构投资者也增加或减少了在 EXAS 的持股。Westside Investment Management Inc. 在第三季度将其在 Exact Sciences 的持股提高了 100.0%。Westside Investment Management Inc. 目前拥有 542 股这家医疗研究公司的股票，价值 31,000 美元，此前在该期间额外购买了 271 股。Country Trust Bank 在第二季度购买了 Exact Sciences 的新股份，价值 32,000 美元。Quent Capital LLC 在第三季度购买了 Exact Sciences 的新股份，价值 48,000 美元。OFI Invest Asset Management 在第三季度将其在 Exact Sciences 的持股增加了 241.2%。OFI Invest Asset Management 目前拥有 1,085 股这家医疗研究公司的股票，价值 59,000 美元，此前在上个季度额外购买了 767 股。最后，Parallel Advisors LLC 在第三季度将其在 Exact Sciences 的持股提高了 47.6%。Parallel Advisors LLC 目前拥有 1,179 股这家医疗研究公司的股票，价值 65,000 美元，此前在该期间额外购买了 380 股。当前 88.82% 的股票由机构投资者持有。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><p>Several research firms recently weighed in on EXAS. William Blair downgraded Exact Sciences from an &#34;outperform&#34; rating to a &#34;market perform&#34; rating in a research report on Thursday, November 20th. Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of Exact Sciences in a research note on Thursday, January 22nd. Evercore set a $105.00 price objective on Exact Sciences and gave the company an &#34;in-line&#34; rating in a research report on Monday, January 5th. Wells Fargo &amp; Company reiterated an &#34;equal weight&#34; rating and set a $105.00 price objective (up from $85.00) on shares of Exact Sciences in a research note on Thursday, November 20th. Finally, Barclays reissued an &#34;equal weight&#34; rating and issued a $105.00 target price (up from $77.00) on shares of Exact Sciences in a report on Thursday, November 20th. Twenty-one analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of &#34;Reduce&#34; and an average price target of $92.13.</p>
<div class="lb-trans"><p>几家研究公司最近对 EXAS 进行了评估。William Blair 在 11 月 20 日的研究报告中将 Exact Sciences 的评级从 “跑赢大盘” 下调至 “市场表现”。Weiss Ratings 在 1 月 22 日的研究报告中重申了对 Exact Sciences 股票的 “卖出 (d-)” 评级。Evercore 在 1 月 5 日的研究报告中设定了 Exact Sciences 的目标价为 105.00 美元，并给予该公司 “持平” 评级。Wells Fargo &amp; Company 在 11 月 20 日的研究报告中重申了 “等权重” 评级，并将 Exact Sciences 的目标价设定为 105.00 美元（上调自 85.00 美元）。最后，Barclays 在 11 月 20 日的报告中重新发布了 “等权重” 评级，并将 Exact Sciences 的目标价设定为 105.00 美元（上调自 77.00 美元）。21 位分析师对该股票给予了持有评级，1 位分析师给予了卖出评级。根据 MarketBeat.com 的数据，该公司目前的平均评级为 “减持”，平均目标价为 92.13 美元。</p>
</div><ul>
<li>3 Hot Stocks Bought by Members of Congress: Follow the Money</li>
</ul>
<div class="lb-trans"><ul>
<li>国会议员购买的 3 只热门股票：跟随资金流动</li>
</ul>
</div><p><strong>View Our Latest Stock Report on Exact Sciences</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 Exact Sciences 股票报告</strong></p>
</div><h2>Exact Sciences Trading Up 0.3%</h2>
<div class="lb-trans"><h2>Exact Sciences 股票上涨 0.3%</h2>
</div><p>Shares of EXAS opened at $103.57 on Friday. The firm has a market cap of $19.77 billion, a P/E ratio of -94.15, a price-to-earnings-growth ratio of 2.36 and a beta of 1.41. The company has a debt-to-equity ratio of 0.97, a current ratio of 2.43 and a quick ratio of 2.17. Exact Sciences Corporation has a 1 year low of $38.81 and a 1 year high of $103.75. The company has a 50 day simple moving average of $102.83 and a two-hundred day simple moving average of $83.86.</p>
<div class="lb-trans"><p>EXAS 的股票在周五开盘价为 103.57 美元。该公司的市值为 197.7 亿美元，市盈率为 -94.15，市盈增长比率为 2.36，贝塔值为 1.41。该公司的债务与股本比率为 0.97，流动比率为 2.43，速动比率为 2.17。Exact Sciences Corporation 的一年低点为 38.81 美元，一年高点为 103.75 美元。该公司的 50 日简单移动平均为 102.83 美元，200 日简单移动平均为 83.86 美元。</p>
</div><ul>
<li>Time to buy these 3 healthcare companies that raised revenue guidance?</li>
</ul>
<div class="lb-trans"><ul>
<li>现在是购买这 3 家提高收入指引的医疗公司吗？</li>
</ul>
</div><p>Exact Sciences (NASDAQ:EXAS - Get Free Report) last released its earnings results on Friday, February 13th. The medical research company reported ($0.21) EPS for the quarter, missing the consensus estimate of $0.08 by ($0.29). Exact Sciences had a positive return on equity of 0.53% and a negative net margin of 6.40%.During the same quarter in the previous year, the company posted ($0.06) earnings per share. The firm's revenue was up 23.1% on a year-over-year basis. On average, equities analysts expect that Exact Sciences Corporation will post -0.58 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Exact Sciences (NASDAQ:EXAS - 获取免费报告) 最近在 2 月 13 日发布了其财报。这家医疗研究公司报告了本季度每股收益为（$0.21），低于共识预期的 $0.08，差距为（$0.29）。Exact Sciences 的股本回报率为 0.53%，净利润率为 -6.40%。在去年同期，该公司每股收益为（$0.06）。该公司的收入同比增长 23.1%。分析师平均预计 Exact Sciences Corporation 本财年的每股收益将为 -0.58。</p>
</div><h2>Exact Sciences Profile</h2>
<div class="lb-trans"><h2>Exact Sciences 公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>(免费报告)</p>
</div><p>Exact Sciences Corporation is a molecular diagnostics company headquartered in Madison, Wisconsin, dedicated to the early detection and prevention of cancer. The company's flagship product, Cologuard®, is a noninvasive, stool-based DNA screening test for colorectal cancer that was developed in collaboration with the Mayo Clinic. By combining DNA mutation analysis with hemoglobin detection, Cologuard aims to improve screening adherence and identify cancers and precancerous lesions in average-risk adults.</p>
<div class="lb-trans"><p>Exact Sciences Corporation 是一家分子诊断公司，总部位于威斯康星州麦迪逊，致力于癌症的早期检测和预防。该公司的旗舰产品 Cologuard® 是一种非侵入性的基于粪便的 DNA 筛查测试，用于结直肠癌，由 Mayo Clinic 合作开发。通过结合 DNA 突变分析和血红蛋白检测，Cologuard 旨在提高筛查依从性，并在平均风险成年人中识别癌症和癌前病变。</p>
</div><p>Since its founding in 1995, Exact Sciences has expanded its portfolio through strategic acquisitions and internal research and development.</p>
<div class="lb-trans"><p>自 1995 年成立以来，Exact Sciences 通过战略收购和内部研发扩展了其产品组合。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Exact Sciences</li>
<li>The gold chart Wall Street is terrified of…</li>
<li>Elon Musk already made me a “wealthy man”</li>
<li>Silver paying 20% dividend. Plus 68% share gains</li>
<li>Unlocked: Elon Musk’s Next Big IPO</li>
<li>A personal warning from Martin Weiss (Please read)</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票超过 Exact Sciences</li>
<li>华尔街害怕的黄金图表……</li>
<li>埃隆·马斯克已经让我成为 “富有的人”</li>
<li>白银支付 20% 股息。此外 68% 的股票收益</li>
<li>解锁：埃隆·马斯克的下一个大 IPO</li>
<li>马丁·韦斯的个人警告（请阅读）</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RVhBUw" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=EXAS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Exact Sciences Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Exact Sciences 吗？</h2>
</div><p>Before you consider Exact Sciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Exact Sciences 之前，你会想听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Exact Sciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Exact Sciences 并不在名单上。</p>
</div><p>While Exact Sciences currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Exact Sciences 目前在分析师中获得了减持评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Ausdal Financial Partners Inc. Buys New Position in Exact Sciences Corporation $EXAS

Market Beat

医药突破 ETF - ALPS

纳斯达克生物科技指数 ETF - iShares Nasdaq

纽交所高增长板生物技术指数 ETF - First Trust

2 倍做多纳斯达克生物技术 ETF - ProShares

生物科技 ETF - VanEck Vectors

基因改革 ETF - ARK

基因免疫&健康关怀 ETF - iShares

精密科学

标普生物技术 3 倍做多 - Direxion

动态生物技术与基因组 ETF - Invesco

Ausdal Financial Partners Inc. 在精密科学公司 $EXAS 中建立了新的投资头寸